Processa Pharmaceuticals (PCSA) AI Stock Analysis

• Market Cap: $7.16M
• Dividend Yield: N/A
• Average Volume (3M): 40.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: 72.88%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.81
• Shares Outstanding: 2,265,769
• 10 Day Avg. Volume: 41,081
• 30 Day Avg. Volume: 40,229
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -6
• Revenue Forecast (FY): $10.01M

• Rating: 45 Neutral
• Price Target: $3.00 ▲(2400.00% Upside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

The score is held down primarily by weak financial performance (no revenue, continued losses, and ongoing cash burn despite low debt), implying meaningful funding risk. Technicals show short-term improvement but a still-weak longer-term trend with elevated momentum readings. Corporate events are mixed, while valuation metrics provide little support due to an uninformative P/E and no dividend yield.

Positive Factors

Low leverage / no debt

Processa's near-zero debt position materially reduces default and interest-rate exposure for a pre-revenue biotech. This durable balance-sheet trait preserves financing optionality, limits fixed-cost obligations, and gives management flexibility to prioritize R&D and partnering strategies over servicing debt.

Nasdaq compliance regained

Resolving minimum-bid noncompliance removes near-term delisting risk and preserves public listing benefits. For a small clinical-stage biotech, continued listing sustains access to equity markets and institutional investors, which is strategically important given ongoing R&D funding needs over the coming quarters.

Focused oncology pipeline and expertise

A concentrated, expertise-driven oncology strategy can create durable competitive advantages: clearer clinical development priorities, targeted trial design, and more credible partnering stories. Specialization in improving established chemotherapies may lower scientific risk versus wholly novel mechanisms.

Negative Factors

No revenue; sustained cash burn

Absence of product revenue and persistent operating cash burn create a structural funding requirement. Over a 2–6 month horizon, this elevates dilution or financing risk, forces management to secure capital, and constrains long-term R&D cadence absent durable non-dilutive partnerships or approved products.

Loss of PCS12852 licensing pathway

Expiration of the Intact term sheet removes a prospective commercialization and development partner for PCS12852, increasing the burden on Processa to self-fund or re-source collaborators. This is a durable strategic setback that can delay timelines and reduce near-term non-dilutive funding opportunities.

Shrinking equity cushion

A materially reduced equity base limits the company's financial cushion against continued losses and heightens vulnerability to funding shocks. Over several months this increases the likelihood of dilution, dependence on partner deals, or constrained operational choices if cash burn persists.

Processa Pharmaceuticals Business Overview & Revenue Model

Company Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

How the Company Makes Money

Processa Pharmaceuticals is a clinical-stage company and, based on publicly available descriptions of its stage and activities, it primarily relies on financing (such as issuing equity and/or other capital-raising transactions) rather than recurring commercial product revenue. Revenue from product sales is null because the company’s drug candidates are in development and not described as marketed products. Potential future revenue sources (if and when candidates are approved) would typically include product sales and/or licensing, collaboration, or partnership agreements (e.g., upfront payments, milestone payments, and royalties), but specific, current revenue-generating partnerships and their financial contributions are null if not explicitly disclosed in available information.

Processa Pharmaceuticals Financial Statement Overview

Summary

Financials reflect an early-stage biotech profile: no revenue across 2020–2025, ongoing net losses (2025 net loss ~-$13.6M), and continued operating/free cash flow burn (~-$11.4M in 2025). Low leverage and no debt reduce balance-sheet risk, but shrinking equity and persistent cash burn imply continued reliance on external funding.

Income Statement

Across 2020–2025, the company reports no revenue and persistent, sizeable net losses (roughly $11M–$27M annually; 2025 net loss of ~$13.6M). Losses narrowed materially versus 2022’s peak loss (~$27.4M), but the business remains pre-commercial with no visible top-line traction in the provided periods, keeping profitability and operating momentum weak.

Balance Sheet

Leverage is very low, with minimal to no debt in recent years (2025 total debt at $0; debt-to-equity near zero historically), which reduces financial risk. However, equity has been volatile and much lower than earlier levels (equity ~$5.6M in 2025 versus ~$25.5M in 2021), and returns on equity are deeply negative due to ongoing losses—signaling continued balance-sheet pressure if cash burn persists.

Cash Flow

Operating and free cash flow are consistently negative, indicating ongoing cash burn (2025 operating/free cash flow about -$11.4M; similar burn in 2024). Cash burn improved from 2022–2023 levels but remains substantial, and cash generation is not yet self-funding given the absence of revenue; this heightens dependence on external financing over time.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	0.00	-12.05M	-11.46M	-19.47M	-10.78M
Net Income	-13.56M	-11.85M	-11.12M	-27.42M	-11.43M
Balance Sheet
Total Assets	7.81M	3.23M	5.79M	8.62M	26.46M
Cash, Cash Equivalents and Short-Term Investments	5.54M	1.19M	4.71M	6.50M	16.50M
Total Debt	0.00	73.51K	150.55K	229.45K	78.46K
Total Liabilities	2.24M	1.53M	797.48K	1.15M	978.40K
Stockholders Equity	5.58M	1.70M	4.99M	7.47M	25.49M
Cash Flow
Free Cash Flow	-11.39M	-11.25M	-8.07M	-9.61M	-8.72M
Operating Cash Flow	-11.39M	-11.25M	-8.06M	-9.61M	-8.72M
Investing Cash Flow	-850.00K	-3.24K	-2.78K	0.00	0.00
Financing Cash Flow	16.58M	7.73M	6.27M	-388.84K	9.80M

Processa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 2.59, below the 50-day MA of 2.78, and below the 200-day MA of 5.36, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 62.33 is Neutral, neither overbought nor oversold. The STOCH value of 81.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PCSA.

Processa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHGE	49 Neutral	$8.03M	-3.61	-154.50%	―	―	54.25%
PCSA	45 Neutral	$7.16M	―	-301.42%	―	―	72.88%
LPCN	45 Neutral	$53.29M	-4.54	-59.29%	―	-44.31%	-34.17%
COCP	45 Neutral	$15.58M	-1.68	-94.94%	―	―	49.10%
SNGX	43 Neutral	$12.31M	-0.50	-267.10%	―	―	53.13%
CANF	41 Neutral	$7.48M	-24.51	―	―	―	―

Processa Pharmaceuticals Corporate Events

Processa Ends PCS12852 Licensing Pact With Intact Therapeutics

On February 12, 2026, Processa Pharmaceuticals, Inc. reported that its Binding Term Sheet dated June 17, 2025 with Intact Therapeutics regarding the drug candidate PCS12852 had expired without the parties executing a definitive license agreement. The related proposed amendment to Processa’s existing License Agreement with Yuhan Corporation was also not entered into, leaving none of the parties with further obligations under the expired Term Sheet and potentially limiting Processa’s previously anticipated development or commercialization plans for PCS12852.

The lapse of the Term Sheet with Intact Therapeutics ended a prospective licensing pathway for PCS12852 that had been under discussion since mid-2025, signaling a shift in Processa’s strategic options for that asset. This development may affect how the company positions PCS12852 within its pipeline and could alter expectations among partners and investors regarding future collaborations or deal structures tied to this program.

The most recent analyst rating on (PCSA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.

Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance

On January 6, 2026, Processa Pharmaceuticals, Inc. announced that it had regained compliance with the Nasdaq Capital Market’s $1.00 minimum closing bid price requirement for continued listing, and Nasdaq has formally closed the matter. This resolution removes an immediate delisting risk for the company’s shares and stabilizes its stock market status, which may provide greater confidence and certainty for investors and other stakeholders.

The most recent analyst rating on (PCSA) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.